Search the Newsreel

EuroHoldings declares $0.14 dividend payable around Sept. 16

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price

Keurig Dr Pepper appoints Aaron Alt to board of directors and audit committee

Keurig Dr Pepper Inc. (NASDAQ:KDP) has announced the appointment of Aaron Alt as an independent member of its board of directors, effective August 14, 2026, increasing the board's size to ten. Mr. Alt will also join the board’s Audit and Finance Committee. This appointment …

Aaron Alt appointed to Keurig Dr Pepper board, joins Audit and Finance Committee

Keurig Dr Pepper has appointed Aaron Alt as an independent director, effective August 14, 2026. He will also serve as a member of the Audit and Finance Committee. This appointment was disclosed in an SEC filing by Keurig Dr Pepper Inc. [KDP] on August …

Keurig Dr Pepper Announces Appointment of New Director to its Board

Keurig Dr Pepper Inc. (NASDAQ: KDP) has announced the appointment of Aaron Alt to its Board of Directors, effective August 14, 2026. Alt, currently CFO of Cardinal Health, brings extensive experience in finance, capital allocation, and business transformation, and will serve on KDP's Audit …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Eureka Forbes Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Euronet Worldwide, Inc. $EEFT Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP reduced its stake in Euronet Worldwide (NASDAQ:EEFT) by 11.3% in the second quarter, selling 58,832 shares but retaining a significant holding valued at $33.7 million. Despite this, other institutional investors increased their positions, and Director Thomas A. McDonnell purchased additional shares, …

HC Wainwright Has Bearish Estimate for NERV Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Minerva Neurosciences (NASDAQ:NERV) to a loss of $0.14 per share, a significant reduction from its previous forecast of a $0.01 loss. The firm also projects a $0.50-per-share loss for the full fiscal year 2026, …

Eureka Forbes Q1 Results: Profit Jumps 46% On One-Time Gain, Revenue Up 15%

Is Coeur Mining (CDE) Undervalued After Record Gold Production And Strong Q2 Results?

Coeur Mining (CDE) is being re-evaluated after reporting record second-quarter gold production, significantly increased sales and net income, and updated full-year production guidance. While the stock has seen mixed short-term performance, its long-term returns have been robust, suggesting an ongoing recovery. Despite these positive …

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, an increase from $17.7 million a year prior, while also announcing the expansion of its ALTO-207 program with plans for an additional Phase 3 trial in treatment-resistant depression. The company secured …

Assenagon Asset Management S.A. Sells 707,062 Shares of Coeur Mining, Inc. $CDE

Firefly Neuroscience Inc. (AIFF) Q3 1998 Earnings: Severe EPS Miss Raises Concerns - Margin Guidance

Projeções de Resultados: Euronet Worldwide Inc (EEFT) — LPA e Crescimento de Receita

Alto Neuroscience (ANRO) Earnings Date and Reports 2026

Neuronetics (STIM) Stock Repriced After Margin Gains And EBITDA Breakeven

Form 8K Neuronetics Inc For: 11 August By Investing.com

This article reports on Neuronetics Inc.'s Form 8K filing for August 11, without providing further details on the content of the filing. It is a brief announcement from Investing.com, typical of financial news outlets reporting SEC filings. The piece primarily serves as a placeholder …

NeuroPace Q2 2026 slides: 21% RNS growth, $55B+ market opportunity

NeuroPace reported strong Q2 2026 results with 21.3% year-over-year revenue growth in its RNS System business, driven by increasing adoption in the adult focal epilepsy market. Despite beating analyst estimates, shares declined due to ongoing losses and regulatory uncertainty surrounding its idiopathic generalized epilepsy …

NeuroPace Raises FY26 Sales Guidance Above Estimates

NeuroPace Inc. has increased its sales guidance for fiscal year 2026 to $99.5 million-$101.5 million, surpassing the consensus estimate of $99.913 million. This upward revision indicates strong demand for its RNS System and improved visibility into recurring revenue, demonstrating the company's confidence in its …

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. reported its second-quarter 2026 financial results, with total revenue reaching $22.8 million and RNS revenue growing 21% to $22.5 million. The company raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million and improved its Adjusted EBITDA loss. NeuroPace …

NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Euro India Fresh Foods Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours

NeuroPace reported Q2 2026 results that exceeded Wall Street expectations for both earnings and revenue, but its shares fell in after-hours trading. The company posted a narrower adjusted loss and 17% revenue growth, driven by strong RNS System sales. Management raised full-year revenue and …

Coeur Mining (CDE) SVP Beckelheimer reports 79,492 shares, mostly unvested stock

Neuropace earnings beat by $0.03, revenue topped estimates

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) reported a Q2 loss of $0.18 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and showing an improvement from a $0.26 loss a year ago. The company also surpassed revenue estimates, posting $22.83 million against a consensus of …

Neuronetics (STIM) grows sales as going concern risk emerges under debt covenants

Neuronetics Inc. reported increased revenues for Q2 and H1 2026, primarily driven by its Greenbrook segment, and narrowed its net loss. However, the company flagged substantial doubt about its ability to continue as a going concern due to a projected failure to meet a …

NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary

NeuroPace Inc reported its second-quarter 2026 results, showing a revenue of $22.8 million, a 17% increase year-over-year. The company posted a net loss attributable to common stockholders of $(6.2) million, with a diluted loss per share of $(0.18), an improvement from $(0.26) in the …

NeuroPace Inc.: Q2 Earnings Snapshot

Press Release: Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Neuronetics, Inc. (NASDAQ: STIM) announced its financial and operating results for the second quarter of 2026. The company reported a significant increase in revenue, driven by strong performance in its capital and treatment session businesses. Neuronetics also provided an updated financial outlook for the …

Neuronetics Q2 Earnings Call Highlights

Neuronetics (STIM) reported significant improvements in its Q2 2026 financial results, including a 9.1% revenue increase to $41.6 million, a sharply narrower net loss of $3.4 million, and positive adjusted EBITDA of $0.3 million. This growth was largely driven by the Greenbrook clinic business …

Coeur Mining: Cash Nears 10x Year-Ago Level At $1.1 Billion As Free Cash Flow Surges 165%

Coeur Mining reported a strong second quarter in 2026, with cash reserves reaching $1.1 billion, nearly 10 times the previous year, and free cash flow surging 165% year-over-year to a record $388 million. This growth was driven by contributions from recent acquisitions, New Afton …

CLWT Stock Surges To 4.5 Year Highs - What Is Euro Tech’s Norwegian Partnership About?